The pharmaceutical sector exists at the junction of research, regulations, and international cooperation. While the leading-edge molecules and innovative therapies take centre stage in the news, the supporting ecosystem of drug development that happens behind the scenes often goes unacknowledged. One of the most important components that is often undervalued is the comparators’ supply of drugs used in the clinical trial, sourcing comparators for a clinical trial, and support from a pharma contract manufacturing company that offers reliable services.
The complexity of clinical trials, being multi-year projects where legitimate comparisons can be performed between investigational medications and established medication will directly impact the accuracy of evaluations regarding efficacy, safety, and therapeutic advantage. Therefore, strategic alliances with contract manufacturers and specialised sourcing partners are crucial to obtaining reformers’ and providers’ compliance throughout the development of investigational medications.
In this blog post, we will discuss the interrelationship between comparator drug sourcing, contract manufacturing expertise, and global supply chain management and how they combine to create effective, compliant, and successful clinical research programs.
Understanding the Role of Comparator Drugs in Clinical Trials
In clinical trials, comparator drugs are drugs that are established, and their use as reference treatments enables researchers to determine whether or not a new investigational product performs better, equally, or worse than currently available therapies.
To measure clinical outcomes, safety profile, and effectiveness, researchers typically compare the outcomes of a comparator group with those of the corresponding group of investigators who received the new investigational treatment.
It is seldom easy to obtain the comparator drugs necessary for conducting clinical trials.
The following are common challenges encountered in obtaining comparator drugs:
- Global Supply Limitations
- Temperature-Controlled Logistics
- Limited Availability Regionally
- Regulatory Differences/Criterion for Labelling
- Batch Traceability/Authenticating Products
Due to the complexities related to obtaining comparator drugs, most pharmaceutical companies utilize specialized organizations that offer supporting supply-chain services with an experienced partnership in manufacturing/distributing comparator drugs.
The Growing Demand for Comparator Drug Supply in Global Research
Increasingly, evidence indicates clinical trials are becoming more global. Previously, pharmaceutical companies conducted research in North America, Europe, Asia, and emerging markets, but now do so simultaneously. Their ability to conduct global trials has increased dramatically, and therefore so too has the challenge of securing comparator medicines.
Global trials require:
- Region-specific product sourcing
- Multilingual labeling and packaging
- Temperature-controlled shipping
- Regulatory compliance in multiple markets
An expert comparator drug supply partner can help to navigate through these requirements so that product integrity is maintained.
As an example, a Phase III oncology clinical study may require thousands of defined doses of a branded reference medicine to be sourced from multiple countries, and without having those available to support all sites in the study, have to be delayed if there is a shortage within one of those countries.
By employing strategic planning and sourcing networks, professional provider partners are able to ensure that there is a continuous supply of comparators; thereby making it easier for sponsors to maintain their timelines for clinical trials as well as ensuring compliance with regulatory agencies.
Comparator Sourcing for Clinical Trials: A Strategic Discipline
Organisations often do not grasp the intricacies of procuring comparator drugs for clinical studies until it is too late and they find themselves dealing with procurement issues.
When procuring comparator medications, there are multiple layers of validity and regulatory compliance, making it more complicated than the standard procurement of pharmaceutical products. There are four main components to consider when procuring comparator products.
1. Validity of Product Authenticity
Counterfeiting drugs is a significant threat in clinical study trials. To prevent counterfeit drug supply, you should rely on your partners of comparator sourcing for clinical trials to verify the Manufacturer’s supply chain through documentation, serial tracking, and regulatory accountability.
2. Consistency of Batches
To ensure the comparability of your clinical study, you must have a consistent batch of the comparator product to compare against the tested study product; any difference in formulations or manufacturing processes could impact the results of your clinical study.
3. Documentation of Regulatory Compliance
Every product obtained from a vendor must contain documents such as:
- Certificate of Analysis (CoA)
- Temperature Excursion Reports
- Import/export documentation
- Regulatory compliance documentation.
Without this documentation, your clinical data could be invalid.
4. Forecasting & Demand Planning
Forecasting demand and avoiding stockouts are very important when conducting clinical trials. Recruitment rates for clinical studies may change quickly, and therefore, a proactive approach to managing your supply of comparator product is important.
Technology’s Growing Role in Comparator Drug Supply
Innovative digital tools are continuously overhauling clinical supply chain operations, in particular, the implementation of technologies that will advance pharmaceutical companies’ ability to efficiently manage, forecast and track comparator medications.
Digital tools will be able to provide key inventions such as:
Blockchain-Based Supply Verification
By utilising Blockchain technology, pharmaceutical companies will be able to create secure methods of tracing a drug’s origin and prevent counterfeiting.
AI-Driven Demand Forecasting
Through the usage of artificial intelligence, enrollment and historical data can be analysed to help predict demand for specific comparator drugs based on geographic location.
Real-Time Shipment Monitoring
Using the Internet of Things (IoT), IoT-enabled temperature sensors monitor environmental conditions during the actual transportation of products to provide evidence that the integrity of the products remains intact.
Through these types of technologies, the operational risk associated with providing comparator drugs for clinical trial purposes has decreased as a result of the overall supply chain management process.
Integrating Manufacturing & Comparator Sourcing Strategies
The integration of manufacturing services with strategies for comparator sourcing for clinical trials is an important component for optimising the clinical trial operation process. By working closely together, a pharma contract manufacturing company and its comparator sourcing specialists can provide numerous benefits to the trial sponsor, which include:
- The ability to coordinate a streamlined supply chain.
- The ability to package and label products in less time.
- The ability to provide better batch traceability.
- The ability to reduce logistical complexity.
By integrating together, the investigational and comparator products will both arrive at the trial site on time and in line with the trial protocol, as well as provide consistent timelines, which is an important factor in the race to develop competitive new drugs.
Risk Management in Comparator Drug Supply
Managing risks associated with sourcing comparator drugs is also a key component of comparator drug supply. Inadequate planning before initiating a clinical trial may result in a disrupted supply of comparator drugs, which may jeopardise the success of the clinical trial.
Some common examples of risks associated with sourcing comparator drugs include:
- Global shortages of drugs.
- Regulatory restrictions relevant to exporting comparator drugs.
- Interruptions in the supply chain.
- Temperature excursions that occur when shipping drugs.
To mitigate these risks, trial sponsors may implement the following strategies:
- Develop a multiple-source procurement strategy.
- Develop a strategic reserve of comparator drug inventory.
- Use regional distribution centres for storing and distributing comparator drugs.
- Conduct continuous supply monitoring.
By taking a proactive approach to risk management, both investigational and comparator drugs will be available for every clinical trial throughout the entire lifecycle of a clinical trial.
Building Long-Term Value Through Strategic Partnerships
To be successful in clinical trials, you need more than clinical expertise; you also need a solid infrastructure, logistics, and supply chain management. To meet these needs, partnering with suppliers who are experienced in the comparator drug supply and sourcing for clinical trials, as well as pharmaceutical manufacturing, will help your company with:
- Speeding up drug development timelines.
- Minimising operational risk.
- Maintaining compliance with regulations.
- Ensuring the availability of clinical supplies consistently.
In this highly competitive sector of the pharmaceutical industry, those who develop strong partnerships with a trusted pharma contract manufacturing company and reliable comparator sourcing specialists will create long-term strategic advantages.
Final Thoughts
Clinical trial success comes from an elaborate network of individuals managing supply chains, production processes, and regulations. Comparator medicines (usually not thought of outside the research community) play an important part in how successful new therapies will be once they receive approval. Availability, authenticity, and quality of the comparator product have a direct impact on how successful a clinical trial will be and whether or not the investigational therapy receives regulatory approval.
By adopting a strategic approach to sourcing comparator drugs, partnering with a reliable pharma contract manufacturing company, and ensuring reliable comparator drug supplies, organisations can improve their infrastructure for conducting clinical research as well as speed up the process of developing new drugs!